Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Deferred Taxes: 2024-2025

Historic Deferred Taxes for Theravance Biopharma (TBPH) over the last 2 years, with Sep 2025 value amounting to $994,000.

  • Theravance Biopharma's Deferred Taxes rose 1004.44% to $994,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.1 million, marking a year-over-year change of. This contributed to the annual value of -$7.6 million for FY2024, which is 336.14% down from last year.
  • Per Theravance Biopharma's latest filing, its Deferred Taxes stood at $994,000 for Q3 2025, which was up 109.30% from -$10.7 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Deferred Taxes registered a high of $994,000 during Q3 2025, and its lowest value of -$10.7 million during Q2 2025.
  • For the 2-year period, Theravance Biopharma's Deferred Taxes averaged around -$2.7 million, with its median value being -$561,000 (2024).
  • Examining YoY changes over the last 5 years, Theravance Biopharma's Deferred Taxes showed a top increase of 1,004.44% in 2025 and a maximum decrease of 1,805.70% in 2025.
  • Over the past 2 years, Theravance Biopharma's Deferred Taxes (Quarterly) stood at -$6.6 million in 2024, then surged by 1,004.44% to $994,000 in 2025.
  • Its last three reported values are $994,000 in Q3 2025, -$10.7 million for Q2 2025, and -$1.9 million during Q1 2025.